Robeco Institutional Asset Management B.V. Uni Qure N.V. Transaction History

Robeco Institutional Asset Management B.V.

$49.7 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Dec 01, 2022	BUY	$14.54 - $21.5 $709,959 - $1.05 Million	48,828 Added 135.34%	84,905 $1.54 Million
Q1 2022 Apr 26, 2022	BUY	$14.54 - $21.5 $709,959 - $1.05 Million	48,828 Added 135.34%	84,905 $1.54 Million
Q4 2021 Dec 01, 2022	BUY	$20.24 - $36.01 $85,999 - $153,006	4,249 Added 13.35%	36,077 $748,000
Q4 2021 Jan 31, 2022	BUY	$20.24 - $36.01 $85,999 - $153,006	4,249 Added 13.35%	36,077 $748,000
Q3 2021 Dec 01, 2022	BUY	$26.01 - $38.22 $827,846 - $1.22 Million	31,828 New	31,828 $1.02 Million
Q3 2021 Oct 20, 2021	BUY	$26.01 - $38.22 $827,846 - $1.22 Million	31,828 New	31,828 $1.02 Million

Others Institutions Holding QURE

# of Institutions

142

Shares Held

35.3M

Call Options Held

1.54M

Put Options Held

389K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Robeco Institutional Asset Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Robeco Institutional Asset Management B.V. with notifications on news.

Account